Contraindications: Absolutely contraindicated with any nitrate medication (organic nitrates or nitric oxide donors) due to severe additive hypotensive risk.
Do not use if taking riociguat (soluble guanylate cyclase stimulator) — combination is contraindicated across all regulatory labels.
Avoid in patients with severe hepatic impairment (Child-Pugh C), as Sildenafil clearance is substantially reduced.
Contraindicated in recent stroke or myocardial infarction (within 6 months) and in hypotension (resting BP < 90/50 mmHg).
Not approved for use in women or in individuals under 18 years of age.
Side Effects: Most common: facial flushing, headache, and nasal congestion — linked to non-selective vasodilation from PDE5 inhibition.
Visual disturbances (blue-tinge perception, blurred vision) may occur transiently; discontinue and seek review if sudden vision loss develops.
Priapism (erection lasting > 4 hours) is a urological emergency requiring immediate medical attention to prevent permanent tissue damage.
Dyspepsia and mild dizziness are reported in a minority of users, particularly when dosed after heavy meals due to erratic plasma level peaks.
Monitoring: Blood pressure should be evaluated before initiating Sildenafil in men with borderline cardiovascular status or those on antihypertensive polypharmacy.
CYP3A4 inhibitors (ketoconazole, erythromycin, certain HIV protease inhibitors) elevate Sildenafil plasma levels; dose reduction may be warranted.
Monitor for orthostatic hypotension symptoms (light-headedness on standing) when Sildenafil is combined with alpha-blockers such as tamsulosin.
PCT: Sildenafil is not a hormonal or androgenic compound and does not suppress the hypothalamic-pituitary-gonadal axis; no post-cycle therapy protocol is required following its use.
If Kamagra Oral Jelly is used alongside anabolic steroids or SARMs, note that those compounds — not Sildenafil — drive the need for PCT; manage hormonal recovery independently.